June 22, 2026 -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a Korean-based company leads the way in biotech innovation with groundbreaking drug research, development, and commercialization worldwide, announced a research and development collaboration at the BIO 2026 International Convention to discover AI-enabled innovative drug candidates in the neuroimmune area of the central nervou

Nura Bio, a neuroscience-focused biotech with a novel approach to treat disorders like amyotrophic lateral sclerosis (ALS), pulled in $73.8 million in a series B funding round to support two clinical programs that could potentially address neurological conditions with high unmet need. ALS, in particular, has been a daunting challenge for drugmakers. Only a select few, including Biogen’s Qalsody, have broken through to the market, leaving patients with limited options to treat a devastating and

Boehringer Ingelheim is committed to improving outcomes for people facing aggressive cancers where there are currently few treatment options DAREON®-Lung-1 and DAREON®-NEC-1 will evaluate obrixtamig, Boehringer's immunoglobin G (IgG)-like bispecific T-cell engager, as a DLL3 biomarker-informed approach designed to help identify patients and inform treatment decisions for small cell lung cancer (SCLC) and extrapulmonary neuroendocrine carcinoma (epNEC)1,2 Beamion LUNG-3 will explore HERNEXEOS® (z

BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the majority of patients previously treated with a covalent BTK inhibitor, reflects current practice patterns These data will be highlighted in a late-breaking oral presentation at the 2026 European Hematology Association (EHA) Annual Meeting June 14, 2026 -- Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-322 clinical trial of Jayp

June 13, 2026 -- Kos Biotechnology Partners ("Kos"), a global life sciences investment firm bridging the US biopharma ecosystem with Europe, today announced the third closing of its inaugural global life sciences fund, bringing total capital commitments to $123M (€106M). Following its initial launch in December 2025, the fund has secured backing from a syndicate of prominent institutional investors—including lead investor Hellenic Development Bank of Investments (HDBI)—and global family offices.

-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures -- -- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS -- -- Company to hold conference call on Saturday, June 13, at 8 a.m. CT, 9 a.m. ET -- June 13, 2026 -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage

June 12, 2026 -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant. Tinlarebant is an investigational, once-daily oral therapy for the treatment of Stargardt disease t

June 12, 2026 -- Transcend Therapeutics today announced the completion of its acquisition by Otsuka America Inc., a subsidiary of Otsuka Pharmaceutical Co., Ltd. (Otsuka), marking a significant milestone in Transcend's mission to develop rapid-acting treatments for neuropsychiatric diseases, including post-traumatic stress disorder (PTSD). The acquisition was originally announced on March 27, 2026. With the completion of the transaction, Transcend is now a wholly owned subsidiary of Otsuka Amer

June 12, 2026 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 3 LAGOON trial, conducted by PharmaMar, evaluating Zepzelca® (lurbinectedin) in patients with relapsed (second-line) metastatic small cell lung cancer (SCLC). The trial did not meet its primary endpoint of overall survival (OS) evaluating Zepzelca as monotherapy or in combination with irinotecan compared to investigators' choice of topotecan or irinotecan. No new safety signals were identifie

June 12, 2026 -- AbbVie (NYSE: ABBV) today announced new Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association (EHA) 2026 Congress taking place June 11-14 in Stockholm, Sweden. Final results from the Phase 3 CLL14 trial in previously untreated chronic lymphocytic leukemia (CLL), which was conducted in collaboration with the German CLL Study Group, will be featured in an oral presentation. "The nine-year results from the landmark Phase 3 CLL14 trial